Cargando…

Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform

Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their hist...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Rachel L., Deming, Damon J., Deming, Meagan E., Yount, Boyd L., Baric, Ralph S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206136/
https://www.ncbi.nlm.nih.gov/pubmed/30393776
http://dx.doi.org/10.1038/s42003-018-0175-7
_version_ 1783366309238538240
author Graham, Rachel L.
Deming, Damon J.
Deming, Meagan E.
Yount, Boyd L.
Baric, Ralph S.
author_facet Graham, Rachel L.
Deming, Damon J.
Deming, Meagan E.
Yount, Boyd L.
Baric, Ralph S.
author_sort Graham, Rachel L.
collection PubMed
description Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their history of emergence events due to their prevalence in zoonotic pools, designing live-attenuated coronavirus vaccines that can be rapidly and broadly implemented is essential for outbreak preparedness. Here, we show that coronaviruses with completely rewired transcription regulatory networks (TRNs) are effective vaccines against SARS-CoV. The TRN-rewired viruses are attenuated and protect against lethal SARS-CoV challenge. While a 3-nt rewired TRN reverts via second-site mutation upon serial passage, a 7-nt rewired TRN is more stable, suggesting that a more extensively rewired TRN might be essential for avoiding growth selection. In summary, rewiring the TRN is a feasible strategy for limiting reversion in an effective live-attenuated coronavirus vaccine candidate that is potentially portable across the Nidovirales order.
format Online
Article
Text
id pubmed-6206136
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62061362018-11-02 Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform Graham, Rachel L. Deming, Damon J. Deming, Meagan E. Yount, Boyd L. Baric, Ralph S. Commun Biol Article Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their history of emergence events due to their prevalence in zoonotic pools, designing live-attenuated coronavirus vaccines that can be rapidly and broadly implemented is essential for outbreak preparedness. Here, we show that coronaviruses with completely rewired transcription regulatory networks (TRNs) are effective vaccines against SARS-CoV. The TRN-rewired viruses are attenuated and protect against lethal SARS-CoV challenge. While a 3-nt rewired TRN reverts via second-site mutation upon serial passage, a 7-nt rewired TRN is more stable, suggesting that a more extensively rewired TRN might be essential for avoiding growth selection. In summary, rewiring the TRN is a feasible strategy for limiting reversion in an effective live-attenuated coronavirus vaccine candidate that is potentially portable across the Nidovirales order. Nature Publishing Group UK 2018-10-29 /pmc/articles/PMC6206136/ /pubmed/30393776 http://dx.doi.org/10.1038/s42003-018-0175-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Graham, Rachel L.
Deming, Damon J.
Deming, Meagan E.
Yount, Boyd L.
Baric, Ralph S.
Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title_full Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title_fullStr Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title_full_unstemmed Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title_short Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
title_sort evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206136/
https://www.ncbi.nlm.nih.gov/pubmed/30393776
http://dx.doi.org/10.1038/s42003-018-0175-7
work_keys_str_mv AT grahamrachell evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform
AT demingdamonj evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform
AT demingmeagane evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform
AT yountboydl evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform
AT baricralphs evaluationofarecombinationresistantcoronavirusasabroadlyapplicablerapidlyimplementablevaccineplatform